Drug Profile
Research programme: glucokinase stimulants - Ligand Pharmaceuticals
Alternative Names: GKA program - Ligand PharmaceuticalsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals
- Class Enzymes
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
- 14 Dec 2012 This glucokinase stimulant research programme is available for licensing as of 14 Dec 2012. http://www.ligand.com
- 14 Dec 2012 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)